1	2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Conventional	_	_	JJ	_	_	_	_	_
2	Mouse	_	_	NN	_	_	_	_	_
3	Models	_	_	NNS	_	_	_	_	_
4	for	_	_	IN	_	_	_	_	_
5	Liver	_	_	NN	_	_	_	_	_
6	Cancer	_	_	NN	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	relatively	_	_	RB	_	_	_	_	_
3	large	_	_	JJ	_	_	_	_	_
4	number	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	mouse	_	_	NN	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	are	_	_	VBP	_	_	_	_	_
9	presently	_	_	RB	_	_	_	_	_
10	available	_	_	JJ	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	study	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	hepatocarcinogenesis	_	_	NN	_	_	_	_	_
16	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	common	_	_	JJ	_	_	_	_	_
3	ones	_	_	NNS	_	_	_	_	_
4	are	_	_	VBP	_	_	_	_	_
5	chemically	_	_	RB	_	_	_	_	_
6	induced	_	_	VBN	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	genetically	_	_	RB	_	_	_	_	_
10	engineered	_	_	VBN	_	_	_	_	_
11	mouse	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	GEM	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	models	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	implantation	_	_	NN	_	_	_	_	_
18	models	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	and	_	_	CC	_	_	_	_	_
21	viral	_	_	JJ	_	_	_	_	_
22	models	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Our	_	_	PRP$	_	_	_	_	_
2	aim	_	_	NN	_	_	_	_	_
3	here	_	_	RB	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	review	_	_	VB	_	_	_	_	_
8	all	_	_	DT	_	_	_	_	_
9	mouse	_	_	NN	_	_	_	_	_
10	models	_	_	NNS	_	_	_	_	_
11	for	_	_	IN	_	_	_	_	_
12	liver	_	_	NN	_	_	_	_	_
13	cancer	_	_	NN	_	_	_	_	_
14	but	_	_	CC	_	_	_	_	_
15	rather	_	_	RB	_	_	_	_	_
16	to	_	_	TO	_	_	_	_	_
17	provide	_	_	VB	_	_	_	_	_
18	examples	_	_	NNS	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	representative	_	_	JJ	_	_	_	_	_
22	ones	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	mostly	_	_	RB	_	_	_	_	_
25	chemically	_	_	RB	_	_	_	_	_
26	induced	_	_	VBN	_	_	_	_	_
27	or	_	_	CC	_	_	_	_	_
28	genetically	_	_	RB	_	_	_	_	_
29	engineered	_	_	VBN	_	_	_	_	_
30	models	_	_	NNS	_	_	_	_	_
31	(	_	_	-LRB-	_	_	_	_	_
32	GEMs	_	_	NNS	_	_	_	_	_
33	)	_	_	-RRB-	_	_	_	_	_
34	that	_	_	WDT	_	_	_	_	_
35	have	_	_	VBP	_	_	_	_	_
36	been	_	_	VBN	_	_	_	_	_
37	integrated	_	_	VBN	_	_	_	_	_
38	to	_	_	TO	_	_	_	_	_
39	genomics	_	_	NNS	_	_	_	_	_
40	of	_	_	IN	_	_	_	_	_
41	human	_	_	JJ	_	_	_	_	_
42	HCCs	_	_	NNS	_	_	_	_	_
43	(	_	_	-LRB-	_	_	_	_	_


1	Figure	_	_	NN	_	_	_	_	_
2	1	_	_	CD	_	_	_	_	_


1	)	_	_	-RRB-	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	2.1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Chemically	_	_	RB	_	_	_	_	_
2	Induced	_	_	VBN	_	_	_	_	_
3	Models	_	_	NNS	_	_	_	_	_


1	Chemically	_	_	RB	_	_	_	_	_
2	induced	_	_	VBN	_	_	_	_	_
3	hepatocarcinogenesis	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	caused	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	an	_	_	DT	_	_	_	_	_
8	irreversible	_	_	JJ	_	_	_	_	_
9	process	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	structural	_	_	JJ	_	_	_	_	_
12	DNA	_	_	NN	_	_	_	_	_
13	changes	_	_	NNS	_	_	_	_	_
14	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	widely	_	_	RB	_	_	_	_	_
4	used	_	_	VBN	_	_	_	_	_
5	chemical	_	_	NN	_	_	_	_	_
6	to	_	_	TO	_	_	_	_	_
7	induce	_	_	VB	_	_	_	_	_
8	liver	_	_	NN	_	_	_	_	_
9	cancer	_	_	NN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	mice	_	_	NNS	_	_	_	_	_
12	is	_	_	VBZ	_	_	_	_	_
13	diethylnitrosamine	_	_	NN	_	_	_	_	_
14	(	_	_	-LRB-	_	_	_	_	_
15	DEN	_	_	NNP	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	(	_	_	-LRB-	_	_	_	_	_
18	Table	_	_	NN	_	_	_	_	_
19	1	_	_	CD	_	_	_	_	_
20	)	_	_	-RRB-	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	DEN	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	DNA	_	_	NN	_	_	_	_	_
5	alkylating	_	_	JJ	_	_	_	_	_
6	agent	_	_	NN	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	when	_	_	WRB	_	_	_	_	_
9	injected	_	_	VBN	_	_	_	_	_
10	into	_	_	IN	_	_	_	_	_
11	juvenile	_	_	JJ	_	_	_	_	_
12	mice	_	_	NNS	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	it	_	_	PRP	_	_	_	_	_
15	forms	_	_	VBZ	_	_	_	_	_
16	mutagenic	_	_	JJ	_	_	_	_	_
17	DNA	_	_	NN	_	_	_	_	_
18	adducts	_	_	NNS	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	which	_	_	WDT	_	_	_	_	_
21	are	_	_	VBP	_	_	_	_	_
22	generated	_	_	VBN	_	_	_	_	_
23	rapidly	_	_	RB	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	centrilobular	_	_	NN	_	_	_	_	_
26	hepatocytes	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	DEN	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	metabolic	_	_	JJ	_	_	_	_	_
4	activated	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	hepatocytes	_	_	NNS	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	enzymes	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	the	_	_	DT	_	_	_	_	_
11	cytochrome	_	_	NN	_	_	_	_	_
12	P450	_	_	NN	_	_	_	_	_
13	family	_	_	NN	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	acts	_	_	VBZ	_	_	_	_	_
16	as	_	_	IN	_	_	_	_	_
17	a	_	_	DT	_	_	_	_	_
18	complete	_	_	JJ	_	_	_	_	_
19	carcinogen	_	_	NN	_	_	_	_	_
20	if	_	_	IN	_	_	_	_	_
21	injected	_	_	VBN	_	_	_	_	_
22	into	_	_	IN	_	_	_	_	_
23	young	_	_	JJ	_	_	_	_	_
24	mice	_	_	NNS	_	_	_	_	_
25	younger	_	_	JJR	_	_	_	_	_
26	than	_	_	IN	_	_	_	_	_
27	two	_	_	CD	_	_	_	_	_
28	weeks	_	_	NNS	_	_	_	_	_
29	old	_	_	JJ	_	_	_	_	_
30	with	_	_	IN	_	_	_	_	_
31	actively	_	_	RB	_	_	_	_	_
32	proliferating	_	_	VBG	_	_	_	_	_
33	hepatocytes	_	_	NNS	_	_	_	_	_
34	resulting	_	_	VBG	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	dysplastic	_	_	JJ	_	_	_	_	_
37	nodules	_	_	NNS	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	which	_	_	WDT	_	_	_	_	_
40	progress	_	_	VBP	_	_	_	_	_
41	to	_	_	TO	_	_	_	_	_
42	carcinoma	_	_	NN	_	_	_	_	_
43	.	_	_	.	_	_	_	_	_


1	If	_	_	IN	_	_	_	_	_
2	given	_	_	VBN	_	_	_	_	_
3	to	_	_	TO	_	_	_	_	_
4	an	_	_	DT	_	_	_	_	_
5	older	_	_	JJR	_	_	_	_	_
6	mouse	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	additional	_	_	JJ	_	_	_	_	_
9	stimulation	_	_	NN	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	required	_	_	VBN	_	_	_	_	_
12	for	_	_	IN	_	_	_	_	_
13	instance	_	_	NN	_	_	_	_	_
14	,	_	_	,	_	_	_	_	_
15	phenobarbital	_	_	NN	_	_	_	_	_
16	(	_	_	-LRB-	_	_	_	_	_
17	PB	_	_	NN	_	_	_	_	_
18	)	_	_	-RRB-	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	carbon	_	_	NN	_	_	_	_	_
21	tetrachloride	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	or	_	_	CC	_	_	_	_	_
24	high-fat	_	_	JJ	_	_	_	_	_
25	diet	_	_	NN	_	_	_	_	_
26	feeding	_	_	NN	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	oxidative	_	_	JJ	_	_	_	_	_
5	stress	_	_	NN	_	_	_	_	_
6	induced	_	_	VBN	_	_	_	_	_
7	by	_	_	IN	_	_	_	_	_
8	reactive	_	_	JJ	_	_	_	_	_
9	oxygen	_	_	NN	_	_	_	_	_
10	species	_	_	NNS	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	ROS	_	_	NNPS	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	during	_	_	IN	_	_	_	_	_
15	DEN	_	_	NN	_	_	_	_	_
16	metabolization	_	_	NN	_	_	_	_	_
17	is	_	_	VBZ	_	_	_	_	_
18	known	_	_	VBN	_	_	_	_	_
19	to	_	_	TO	_	_	_	_	_
20	contribute	_	_	VB	_	_	_	_	_
21	to	_	_	TO	_	_	_	_	_
22	hepatocarcinogenesis	_	_	NN	_	_	_	_	_
23	as	_	_	IN	_	_	_	_	_
24	they	_	_	PRP	_	_	_	_	_
25	cause	_	_	VBP	_	_	_	_	_
26	DNA	_	_	NN	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	protein	_	_	NN	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	and	_	_	CC	_	_	_	_	_
31	lipid	_	_	NN	_	_	_	_	_
32	damage	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	mutational	_	_	JJ	_	_	_	_	_
3	landscape	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	a	_	_	DT	_	_	_	_	_
6	DEN-induced	_	_	JJ	_	_	_	_	_
7	tumor	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	described	_	_	VBN	_	_	_	_	_
10	in	_	_	IN	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	recent	_	_	JJ	_	_	_	_	_
13	study	_	_	NN	_	_	_	_	_
14	using	_	_	VBG	_	_	_	_	_
15	the	_	_	DT	_	_	_	_	_
16	whole	_	_	JJ	_	_	_	_	_
17	exome	_	_	NN	_	_	_	_	_
18	sequencing	_	_	NN	_	_	_	_	_
19	technique	_	_	NN	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	A	_	_	DT	_	_	_	_	_
2	high	_	_	JJ	_	_	_	_	_
3	burden	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	somatic	_	_	JJ	_	_	_	_	_
6	mutation	_	_	NN	_	_	_	_	_
7	was	_	_	VBD	_	_	_	_	_
8	observed	_	_	VBN	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	almost	_	_	RB	_	_	_	_	_
11	all	_	_	DT	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	DNA	_	_	NN	_	_	_	_	_
15	changes	_	_	NNS	_	_	_	_	_
16	in	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	DEN-induced	_	_	JJ	_	_	_	_	_
19	tumors	_	_	NNS	_	_	_	_	_
20	were	_	_	VBD	_	_	_	_	_
21	single-base	_	_	JJ	_	_	_	_	_
22	substitutions	_	_	NNS	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_
24	Four	_	_	CD	_	_	_	_	_
25	recurrently	_	_	RB	_	_	_	_	_
26	mutated	_	_	VBN	_	_	_	_	_
27	genes	_	_	NNS	_	_	_	_	_
28	that	_	_	WDT	_	_	_	_	_
29	are	_	_	VBP	_	_	_	_	_
30	putative	_	_	JJ	_	_	_	_	_
31	oncogenic	_	_	JJ	_	_	_	_	_
32	drivers	_	_	NNS	_	_	_	_	_
33	of	_	_	IN	_	_	_	_	_
34	DEN-induced	_	_	JJ	_	_	_	_	_
35	tumors	_	_	NNS	_	_	_	_	_
36	were	_	_	VBD	_	_	_	_	_
37	Hras	_	_	NNP	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	Braf	_	_	NNP	_	_	_	_	_
40	,	_	_	,	_	_	_	_	_
41	Egfr	_	_	NNP	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	and	_	_	CC	_	_	_	_	_
44	Apc	_	_	NNP	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	incidence	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	Hras	_	_	NNP	_	_	_	_	_
5	was	_	_	VBD	_	_	_	_	_
6	the	_	_	DT	_	_	_	_	_
7	highest	_	_	JJS	_	_	_	_	_
8	reaching	_	_	VBG	_	_	_	_	_
9	approximately	_	_	RB	_	_	_	_	_
10	80	_	_	CD	_	_	_	_	_
11	%	_	_	NN	_	_	_	_	_
12	suggesting	_	_	VBG	_	_	_	_	_
13	selective	_	_	JJ	_	_	_	_	_
14	advantage	_	_	NN	_	_	_	_	_
15	during	_	_	IN	_	_	_	_	_
16	hepatocarcinogenesis	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	Hras	_	_	NNP	_	_	_	_	_


1	,	_	_	,	_	_	_	_	_
2	Braf	_	_	NNP	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	and	_	_	CC	_	_	_	_	_
5	Egfr	_	_	NNP	_	_	_	_	_
6	mutations	_	_	NNS	_	_	_	_	_
7	were	_	_	VBD	_	_	_	_	_
8	present	_	_	JJ	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	every	_	_	DT	_	_	_	_	_
11	DEN-induced	_	_	JJ	_	_	_	_	_
12	HCC	_	_	NN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	mutual	_	_	JJ	_	_	_	_	_
15	exclusivity	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	may	_	_	MD	_	_	_	_	_
18	replace	_	_	VB	_	_	_	_	_
19	each	_	_	DT	_	_	_	_	_
20	other	_	_	JJ	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	terms	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	oncogenic	_	_	JJ	_	_	_	_	_
25	drivers	_	_	NNS	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Activation	_	_	NN	_	_	_	_	_
2	of	_	_	IN	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	Ras/Raf/MEK/ERK	_	_	NNP	_	_	_	_	_
5	signal	_	_	NN	_	_	_	_	_
6	transduction	_	_	NN	_	_	_	_	_
7	pathway	_	_	NN	_	_	_	_	_
8	was	_	_	VBD	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	hallmark	_	_	NN	_	_	_	_	_
11	feature	_	_	NN	_	_	_	_	_
12	in	_	_	IN	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	DEN-induced	_	_	JJ	_	_	_	_	_
15	mouse	_	_	NN	_	_	_	_	_
16	model	_	_	NN	_	_	_	_	_
17	which	_	_	WDT	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	rare	_	_	JJ	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	human	_	_	JJ	_	_	_	_	_
22	HCC	_	_	NN	_	_	_	_	_
23	.	_	_	.	_	_	_	_	_


1	Of	_	_	IN	_	_	_	_	_
2	note	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	TP53	_	_	NNP	_	_	_	_	_
5	and	_	_	CC	_	_	_	_	_
6	CTNNB1	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	most	_	_	RBS	_	_	_	_	_
10	frequently	_	_	RB	_	_	_	_	_
11	altered	_	_	VBN	_	_	_	_	_
12	genes	_	_	NNS	_	_	_	_	_
13	in	_	_	IN	_	_	_	_	_
14	human	_	_	NN	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	never	_	_	RB	_	_	_	_	_
17	found	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	DEN-induced	_	_	JJ	_	_	_	_	_
20	tumors	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Although	_	_	IN	_	_	_	_	_
2	ctnnb1	_	_	NN	_	_	_	_	_
3	mutation	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	not	_	_	RB	_	_	_	_	_
6	observed	_	_	VBN	_	_	_	_	_
7	in	_	_	IN	_	_	_	_	_
8	DEN-induced	_	_	JJ	_	_	_	_	_
9	model	_	_	NN	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	its	_	_	PRP$	_	_	_	_	_
12	mutation	_	_	NN	_	_	_	_	_
13	is	_	_	VBZ	_	_	_	_	_
14	known	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	be	_	_	VB	_	_	_	_	_
17	observed	_	_	VBN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	a	_	_	DT	_	_	_	_	_
20	two-stage	_	_	JJ	_	_	_	_	_
21	model	_	_	NN	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	DEN-initiated	_	_	JJ	_	_	_	_	_
25	and	_	_	CC	_	_	_	_	_
26	PB-promoted	_	_	JJ	_	_	_	_	_
27	protocol	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	addition	_	_	NN	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	loss	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	Apc	_	_	NNP	_	_	_	_	_
7	function	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	mutation	_	_	NN	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	aberrant	_	_	JJ	_	_	_	_	_
12	nuclear	_	_	JJ	_	_	_	_	_
13	expression	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	β-catenin	_	_	NN	_	_	_	_	_
16	may	_	_	MD	_	_	_	_	_
17	disrupt	_	_	VB	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	canonical	_	_	JJ	_	_	_	_	_
20	Wnt/β-catenin	_	_	NN	_	_	_	_	_
21	pathway	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	Stelic	_	_	NNP	_	_	_	_	_
3	Animal	_	_	NNP	_	_	_	_	_
4	Model	_	_	NNP	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	STAM	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	demonstrates	_	_	VBZ	_	_	_	_	_
9	non-alcoholic	_	_	JJ	_	_	_	_	_
10	steatohepatitis	_	_	NN	_	_	_	_	_
11	(	_	_	-LRB-	_	_	_	_	_
12	NASH	_	_	NNP	_	_	_	_	_
13	)	_	_	-RRB-	_	_	_	_	_
14	progression	_	_	NN	_	_	_	_	_
15	resembling	_	_	VBG	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	disease	_	_	NN	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	humans	_	_	NNS	_	_	_	_	_
20	.	_	_	.	_	_	_	_	_


1	Since	_	_	IN	_	_	_	_	_
2	NASH	_	_	NNP	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	evolving	_	_	VBG	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	a	_	_	DT	_	_	_	_	_
7	major	_	_	JJ	_	_	_	_	_
8	cause	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	non-viral	_	_	JJ	_	_	_	_	_
11	HCC	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	may	_	_	MD	_	_	_	_	_
14	account	_	_	VB	_	_	_	_	_
15	for	_	_	IN	_	_	_	_	_
16	a	_	_	DT	_	_	_	_	_
17	large	_	_	JJ	_	_	_	_	_
18	proportion	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	HCC	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	developed	_	_	VBN	_	_	_	_	_
23	countries	_	_	NNS	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	recent	_	_	JJ	_	_	_	_	_
26	years	_	_	NNS	_	_	_	_	_
27	,	_	_	,	_	_	_	_	_
28	HCC	_	_	NNP	_	_	_	_	_
29	arising	_	_	VBG	_	_	_	_	_
30	from	_	_	IN	_	_	_	_	_
31	NASH	_	_	NNP	_	_	_	_	_
32	is	_	_	VBZ	_	_	_	_	_
33	important	_	_	JJ	_	_	_	_	_
34	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	STAM	_	_	NNP	_	_	_	_	_
3	model	_	_	NN	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	created	_	_	VBN	_	_	_	_	_
6	by	_	_	IN	_	_	_	_	_
7	combination	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	chemical	_	_	NN	_	_	_	_	_
10	(	_	_	-LRB-	_	_	_	_	_
11	a	_	_	DT	_	_	_	_	_
12	single	_	_	JJ	_	_	_	_	_
13	subcutaneous	_	_	JJ	_	_	_	_	_
14	injection	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	200	_	_	CD	_	_	_	_	_
17	μg	_	_	NN	_	_	_	_	_
18	of	_	_	IN	_	_	_	_	_
19	streptozotocin	_	_	NN	_	_	_	_	_
20	at	_	_	IN	_	_	_	_	_
21	two	_	_	CD	_	_	_	_	_
22	days	_	_	NNS	_	_	_	_	_
23	after	_	_	IN	_	_	_	_	_
24	birth	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	and	_	_	CC	_	_	_	_	_
27	dietary	_	_	JJ	_	_	_	_	_
28	intervention	_	_	NN	_	_	_	_	_
29	(	_	_	-LRB-	_	_	_	_	_
30	high-fat	_	_	JJ	_	_	_	_	_
31	diet	_	_	NN	_	_	_	_	_
32	ad	_	_	NN	_	_	_	_	_
33	libitum	_	_	NN	_	_	_	_	_
34	four	_	_	CD	_	_	_	_	_
35	weeks	_	_	NNS	_	_	_	_	_
36	after	_	_	IN	_	_	_	_	_
37	injection	_	_	NN	_	_	_	_	_
38	)	_	_	-RRB-	_	_	_	_	_
39	in	_	_	IN	_	_	_	_	_
40	C57BL/6	_	_	NNP	_	_	_	_	_
41	mice	_	_	NNS	_	_	_	_	_
42	.	_	_	.	_	_	_	_	_


1	STAM	_	_	NNP	_	_	_	_	_
2	mice	_	_	NNS	_	_	_	_	_
3	manifest	_	_	VBP	_	_	_	_	_
4	NASH	_	_	NNP	_	_	_	_	_
5	at	_	_	IN	_	_	_	_	_
6	eight	_	_	CD	_	_	_	_	_
7	weeks	_	_	NNS	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	which	_	_	WDT	_	_	_	_	_
10	progresses	_	_	VBZ	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	fibrosis	_	_	NN	_	_	_	_	_
13	at	_	_	IN	_	_	_	_	_
14	12	_	_	CD	_	_	_	_	_
15	weeks	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	eventually	_	_	RB	_	_	_	_	_
19	develops	_	_	VBZ	_	_	_	_	_
20	into	_	_	IN	_	_	_	_	_
21	HCC	_	_	NNP	_	_	_	_	_
22	at	_	_	IN	_	_	_	_	_
23	a	_	_	DT	_	_	_	_	_
24	rate	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	nearly	_	_	RB	_	_	_	_	_
27	100	_	_	CD	_	_	_	_	_
28	%	_	_	NN	_	_	_	_	_
29	in	_	_	IN	_	_	_	_	_
30	males	_	_	NNS	_	_	_	_	_
31	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	STAM	_	_	NNP	_	_	_	_	_
3	model	_	_	NN	_	_	_	_	_
4	had	_	_	VBD	_	_	_	_	_
5	pathway	_	_	NN	_	_	_	_	_
6	mutation	_	_	NN	_	_	_	_	_
7	rates	_	_	NNS	_	_	_	_	_
8	comparable	_	_	JJ	_	_	_	_	_
9	to	_	_	TO	_	_	_	_	_
10	those	_	_	DT	_	_	_	_	_
11	in	_	_	IN	_	_	_	_	_
12	humans	_	_	NNS	_	_	_	_	_
13	for	_	_	IN	_	_	_	_	_
14	most	_	_	JJS	_	_	_	_	_
15	pathways	_	_	NNS	_	_	_	_	_
16	with	_	_	IN	_	_	_	_	_
17	more	_	_	JJR	_	_	_	_	_
18	alterations	_	_	NNS	_	_	_	_	_
19	in	_	_	IN	_	_	_	_	_
20	receptor	_	_	NN	_	_	_	_	_
21	tyrosine	_	_	NN	_	_	_	_	_
22	kinase	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	RTK	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	signaling	_	_	NN	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	chromatin-modification	_	_	NN	_	_	_	_	_
29	genes	_	_	NNS	_	_	_	_	_
30	.	_	_	.	_	_	_	_	_


1	This	_	_	DT	_	_	_	_	_
2	model	_	_	NN	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	showed	_	_	VBD	_	_	_	_	_
5	low	_	_	JJ	_	_	_	_	_
6	mutation	_	_	NN	_	_	_	_	_
7	rate	_	_	NN	_	_	_	_	_
8	of	_	_	IN	_	_	_	_	_
9	TP53	_	_	NN	_	_	_	_	_
10	but	_	_	CC	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	cell-cycle	_	_	NN	_	_	_	_	_
13	pathway	_	_	NN	_	_	_	_	_
14	alteration	_	_	NN	_	_	_	_	_
15	rate	_	_	NN	_	_	_	_	_
16	was	_	_	VBD	_	_	_	_	_
17	similar	_	_	JJ	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	human	_	_	JJ	_	_	_	_	_
20	tumors	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	limitation	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	this	_	_	DT	_	_	_	_	_
5	model	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	that	_	_	IN	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	model	_	_	NN	_	_	_	_	_
10	does	_	_	VBZ	_	_	_	_	_
11	not	_	_	RB	_	_	_	_	_
12	show	_	_	VB	_	_	_	_	_
13	obesity	_	_	NN	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	insulin	_	_	NN	_	_	_	_	_
16	resistance	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	which	_	_	WDT	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	the	_	_	DT	_	_	_	_	_
21	common	_	_	JJ	_	_	_	_	_
22	characteristics	_	_	NNS	_	_	_	_	_
23	of	_	_	IN	_	_	_	_	_
24	patients	_	_	NNS	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	NASH	_	_	NNP	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	2.2	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Genetically	_	_	RB	_	_	_	_	_
2	Engineered	_	_	VBN	_	_	_	_	_
3	Mouse	_	_	NN	_	_	_	_	_
4	Models	_	_	NNS	_	_	_	_	_


1	Genetically	_	_	RB	_	_	_	_	_
2	engineered	_	_	VBN	_	_	_	_	_
3	mouse	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	GEM	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	models	_	_	NNS	_	_	_	_	_
8	recapitulate	_	_	VBP	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	multistep	_	_	JJ	_	_	_	_	_
11	process	_	_	NN	_	_	_	_	_
12	of	_	_	IN	_	_	_	_	_
13	hepatocarcinogenesis	_	_	NN	_	_	_	_	_
14	with	_	_	IN	_	_	_	_	_
15	multiple	_	_	JJ	_	_	_	_	_
16	genetic	_	_	JJ	_	_	_	_	_
17	and	_	_	CC	_	_	_	_	_
18	epigenetic	_	_	JJ	_	_	_	_	_
19	changes	_	_	NNS	_	_	_	_	_
20	occurring	_	_	VBG	_	_	_	_	_
21	along	_	_	IN	_	_	_	_	_
22	each	_	_	DT	_	_	_	_	_
23	stage	_	_	NN	_	_	_	_	_
24	of	_	_	IN	_	_	_	_	_
25	progression	_	_	NN	_	_	_	_	_
26	toward	_	_	IN	_	_	_	_	_
27	cancer	_	_	NN	_	_	_	_	_
28	formation	_	_	NN	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	They	_	_	PRP	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	highly	_	_	RB	_	_	_	_	_
4	useful	_	_	JJ	_	_	_	_	_
5	for	_	_	IN	_	_	_	_	_
6	assessing	_	_	VBG	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	impacts	_	_	NNS	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	a	_	_	DT	_	_	_	_	_
11	driver	_	_	NN	_	_	_	_	_
12	oncogene	_	_	NN	_	_	_	_	_
13	alone	_	_	RB	_	_	_	_	_
14	or	_	_	CC	_	_	_	_	_
15	in	_	_	IN	_	_	_	_	_
16	combination	_	_	NN	_	_	_	_	_
17	with	_	_	IN	_	_	_	_	_
18	other	_	_	JJ	_	_	_	_	_
19	driver	_	_	NN	_	_	_	_	_
20	oncogenes	_	_	NNS	_	_	_	_	_
21	or	_	_	CC	_	_	_	_	_
22	tumor	_	_	NN	_	_	_	_	_
23	suppressors	_	_	NNS	_	_	_	_	_
24	.	_	_	.	_	_	_	_	_


1	Recently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	Cancer	_	_	NNP	_	_	_	_	_
5	Genome	_	_	NNP	_	_	_	_	_
6	Atlas	_	_	NNP	_	_	_	_	_
7	(	_	_	-LRB-	_	_	_	_	_
8	TCGA	_	_	NNP	_	_	_	_	_
9	)	_	_	-RRB-	_	_	_	_	_
10	characterized	_	_	VBD	_	_	_	_	_
11	the	_	_	DT	_	_	_	_	_
12	genomic	_	_	JJ	_	_	_	_	_
13	landscape	_	_	NN	_	_	_	_	_
14	of	_	_	IN	_	_	_	_	_
15	HCC	_	_	NNP	_	_	_	_	_
16	using	_	_	VBG	_	_	_	_	_
17	large-scale	_	_	JJ	_	_	_	_	_
18	multi-platform	_	_	JJ	_	_	_	_	_
19	analysis	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	HCC	_	_	NNP	_	_	_	_	_
22	,	_	_	,	_	_	_	_	_
23	including	_	_	VBG	_	_	_	_	_
24	evaluation	_	_	NN	_	_	_	_	_
25	of	_	_	IN	_	_	_	_	_
26	somatic	_	_	JJ	_	_	_	_	_
27	mutations	_	_	NNS	_	_	_	_	_
28	and	_	_	CC	_	_	_	_	_
29	copy	_	_	NN	_	_	_	_	_
30	number	_	_	NN	_	_	_	_	_
31	alterations	_	_	NNS	_	_	_	_	_
32	.	_	_	.	_	_	_	_	_


1	Commonly	_	_	RB	_	_	_	_	_
2	altered	_	_	VBN	_	_	_	_	_
3	pathways	_	_	NNS	_	_	_	_	_
4	such	_	_	JJ	_	_	_	_	_
5	as	_	_	IN	_	_	_	_	_
6	cell	_	_	NN	_	_	_	_	_
7	cycle	_	_	NN	_	_	_	_	_
8	pathway	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	RTK/RAS/PI3K	_	_	NNP	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	WNT	_	_	NN	_	_	_	_	_
14	pathways	_	_	NNS	_	_	_	_	_
15	were	_	_	VBD	_	_	_	_	_
16	also	_	_	RB	_	_	_	_	_
17	identified	_	_	VBN	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	therefore	_	_	RB	_	_	_	_	_
20	,	_	_	,	_	_	_	_	_
21	data	_	_	NNS	_	_	_	_	_
22	generated	_	_	VBN	_	_	_	_	_
23	from	_	_	IN	_	_	_	_	_
24	GEMs	_	_	NNS	_	_	_	_	_
25	would	_	_	MD	_	_	_	_	_
26	be	_	_	VB	_	_	_	_	_
27	useful	_	_	JJ	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	developing	_	_	VBG	_	_	_	_	_
30	novel	_	_	JJ	_	_	_	_	_
31	therapies	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	be	_	_	VB	_	_	_	_	_
34	tested	_	_	VBN	_	_	_	_	_
35	in	_	_	IN	_	_	_	_	_
36	the	_	_	DT	_	_	_	_	_
37	preclinical	_	_	JJ	_	_	_	_	_
38	setting	_	_	NN	_	_	_	_	_
39	if	_	_	IN	_	_	_	_	_
40	they	_	_	PRP	_	_	_	_	_
41	recapitulate	_	_	VBP	_	_	_	_	_
42	human	_	_	JJ	_	_	_	_	_
43	HCCs	_	_	NNP	_	_	_	_	_
44	.	_	_	.	_	_	_	_	_

